Biogen Inc. (NASDAQ:BIIB) Overview: Key Developments and Financial Performance

Core Insights - Biogen Inc. is a leading biotechnology company focused on developing treatments for neurological diseases, particularly Alzheimer's disease, in collaboration with Eisai Co., Ltd. [1][6] - UBS has set a price target of $185 for Biogen, indicating optimism about the company's growth potential in the Alzheimer's treatment market [2] - The acceptance of the Biologics License Application for LEQEMBI's subcutaneous formulation in China is a significant milestone that could enhance Biogen's market presence in Asia [3][6] Financial Performance - Biogen's stock has shown resilience with a 15.1% increase in 2025, driven by the successful launch of LEQEMBI and a 29.9% increase in sales for Skyclarys, which reached $132.9 million in the third quarter [4][6] - Currently, Biogen's stock is trading at $182.61, reflecting a 4.57% increase, with fluctuations between $174.30 and $182.97 [5] - Over the past year, Biogen's stock reached a high of $185.17 and a low of $110.04, with a market capitalization of approximately $26.79 billion [5]